Objective: To analyze and compare therapy responses, outcomes, and incidence of severe hematologic adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia (CML) . Methods: Data of patients with chronic phase CML diagnosed between January 2006 and November 2022 from 76 centers, aged ≥18 years, and received initial flumatinib or imatinib therapy within 6 months after diagnosis in China were retrospectively interrogated. Propensity score matching (PSM) analysis was performed to reduce the bias of the initial TKI selection, and the therapy responses and outcomes of patients receiving initial flumatinib or imatinib therapy were compared. Results: A total of 4 833 adult patients with CML receiving initial imatinib (n=4 380) or flumatinib (n=453) therapy were included in the study. In the imatinib cohort, the median follow-up time was 54 [interquartile range (IQR), 31-85] months, and the 7-year cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) were 95.2%, 88.4%, 78.3%, and 63.0%, respectively. The 7-year FFS, PFS, and OS rates were 71.8%, 93.0%, and 96.9%, respectively. With the median follow-up of 18 (IQR, 13-25) months in the flumatinib cohort, the 2-year cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) were 95.4%, 86.5%, 58.4%, and 46.6%, respectively. The 2-year FFS, PFS, and OS rates were 80.1%, 95.0%, and 99.5%, respectively. The PSM analysis indicated that patients receiving initial flumatinib therapy had significantly higher cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) and higher probabilities of FFS than those receiving the initial imatinib therapy (all P<0.001), whereas the PFS (P=0.230) and OS (P=0.268) were comparable between the two cohorts. The incidence of severe hematologic adverse events (grade≥Ⅲ) was comparable in the two cohorts. Conclusion: Patients receiving initial flumatinib therapy had higher cumulative incidences of therapy responses and higher probability of FFS than those receiving initial imatinib therapy, whereas the incidence of severe hematologic adverse events was comparable between the two cohorts.
Adult ; Humans ; Adolescent ; Imatinib Mesylate/adverse effects* ; Incidence ; Antineoplastic Agents/adverse effects* ; Retrospective Studies ; Pyrimidines/adverse effects* ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy* ; Treatment Outcome ; Benzamides/adverse effects* ; Leukemia, Myeloid, Chronic-Phase/drug therapy* ; Aminopyridines/therapeutic use* ; Protein Kinase Inhibitors/therapeutic use*

Flavonoids are a kind of ubiquitous natural products in plants and essential active ingredients of many medicinal plants. They have the characteristics of broad biological activity, high efficiency and low toxicity, with good prevention and cure effects on various types of tumors. Breast cancer is the commonest cancer disease and the main cause of cancer death in women worldwide. In China, the morbidity and mortality are still on the rise. Flavonoids can inhibit the occurrence and development of breast cancer in various aspects. The main mechanisms include the inhibition of aerobic glycolysis, the promotion of apoptosis, the retardation of cell cycle, the suppression of invasion and migration, the induction of DNA damage, and the inhibition of aromatase and microtubule production. Due to its chemical structure similar to estrogen, flavonoids have unique advantages in the prevention and treatment of breast cancer. In this paper, studies on anti-breast cancer of flavonoids in recent years were reviewed, which could provide reference for further studies.

Objective To explore the changes of detection of urine a1-MG and KNG1 in simple type 2 diabetes mellitus and diabetic nephropathy patients.Methods 66 cases of diabetic patients in General Hospital of Ningxia Medical University from September 2016 to March 2017 were recruited,and the patients were divided into two groups,as follows:the diabetic nephropathy (DN) group 34 cases as experimental group,and the simple type 2 diabetes mellitus (DM) group 32 cases as control group.Than DN group was divided into two groups according to HbAlc,A groups 19 cases HbAlc was less than 10％,B groups 15 cases HbAlc was greater than or equal to 10％.The urine α1-MG,urine KNG1 and other biochemical indicators were mearured for all subjects.Results Compared with the DM group,the urine α1-MG in DN group was significantly lower (t=9.972,P＜0.01),but the result of the urine KNG1 was the opposite (t=-3.356,P＜0.01).The urine α1-MG and serum GLU in B group were significantly higher than those of the A group (t=-2.092,-3.464,all P＜0.05),but the result of the serum Cr was the opposite (t=2.181,P＜0.05).The level of urine α1-MG in DN group were positively correlated with HbAlc and urine KNG1 (r=0.33,0.355,all P＜0.05).Conclusion There were some changes in the expression of urine α1-MG and KNG1 in the occurrence and development of diabetic nephropathy,which provide the basis for the clinical diagnosis of diabetic nephropathy.

Twelve flavonoid glycosides were involved in the biotransformation of the glycosyl moieties by Curvularia lunata 3.4381, and the products were analyzed by UPLC/PDA-Q-TOF-MS(E). Curvularia lunata displayed hydrolyzing activities on the terminal Rha or Glc units of some flavonoid glycosides. Terminal Rha with a 1 → 2 linkage of isorhamnetin-3-O-neohesperidoside and typhaneoside could be hydrolyzed by Curvularia lunata, but terminal Rha with a 1 → 6 linkage of rutin, typhaneoside, and quercetin-3-O-apiosyl-(1 → 2)-[rhamnosyl-(1 → 6)]-glucoside could not be hydrolyzed. Curvularia lunata could also hydrolyze the Glc of icariin, floramanoside B, and naringin. This is the first report of the hydrolysis of glycosyl units of flavonoid glycosides by Curvularia lunata. A new way to convert naringin to naringenin was found in this research.
Ascomycota ; chemistry ; Flavonoids ; chemistry ; Glucosides ; chemistry ; Hydrolysis ; Mass Spectrometry ; Molecular Structure